Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared a post on LinkedIn about a recent article he and colleagues authored:
“Excited to share our accompanying editorial to the 5-year update of the NATALEE trial on ESMO Open!
Beyond a simplistic ‘for or against’ view on adjuvant CDK4/6 inhibitors, we asked:
‘Do all patients with early breast cancer meeting the NATALEE criteria benefit from adjuvant ribociclib?’
-with Giuseppe Curigliano and Dario Trapani.”
Title: Do all patients with early breast cancer meeting the NATALEE criteria benefit from adjuvant ribociclib?
Authors: C. Valenza, D. Trapani, G. Curigliano
Read the Full Article in ESMO Open.
More posts featuring Carmine Valenza on OncoDaily.